US Broker Ratings

Royalty Pharma plc (RPRX) Stock Analysis: A 9% Upside Potential with Strong Buy Ratings

Royalty Pharma plc (NASDAQ: RPRX) stands out in the biotechnology sector with its unique business model of acquiring biopharmaceutical royalties and funding innovation across various therapeutic areas. With a market..

Merit Medical Systems, Inc. (MMSI): Exploring a 26.39% Potential Upside with Strong Buy Ratings

Investors eyeing opportunities in the healthcare sector may find Merit Medical Systems, Inc. (NASDAQ: MMSI) an intriguing prospect. With a market capitalization of $4.89 billion, this American company is a..

Madrigal Pharmaceuticals, Inc. (MDGL) Investor Outlook: Analyzing a Potential 39% Upside in Biotech

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is capturing the attention of investors with the promise of significant growth within the biotechnology sector. With a market capitalization of $10.85 billion, Madrigal is..

Revolution Medicines, Inc. (RVMD) Stock Analysis: Exploring a 22.44% Potential Upside in the Biotech Sector

Revolution Medicines, Inc. (NASDAQ: RVMD) is making waves in the biotechnology sector with its focus on developing targeted therapies for RAS-addicted cancers. The company, founded in 2014 and headquartered in..

Exact Sciences Corporation (EXAS) Stock Analysis: A 2.55% Upside in a Booming Healthcare Sector

Exact Sciences Corporation (NASDAQ: EXAS) is commanding attention in the healthcare sector, particularly within the diagnostics and research industry. With a market capitalization of $19.6 billion, this innovative company has..

argenx SE (ARGX) Stock Analysis: Exploring a 27.65% Potential Upside in the Biotech Sector

argenx SE (NASDAQ: ARGX) stands as a formidable player in the biotechnology industry, particularly within the realm of autoimmune disease therapies. With a market capitalization of $50.22 billion, this Netherlands-based..

Vaxcyte, Inc. (PCVX)

⚠️ No article content returned.

..

BridgeBio Pharma, Inc. (BBIO) Stock Analysis: Unveiling a 37.11% Potential Upside in the Biotech Sector

BridgeBio Pharma, Inc. (NASDAQ: BBIO), a leading player in the biotechnology sector, is drawing significant interest from investors, evidenced by a substantial market capitalization of $13.04 billion. The company, headquartered..

ADMA Biologics Inc (ADMA) Stock Analysis: Attractive 56.22% Upside Potential for Investors

ADMA Biologics Inc (NASDAQ: ADMA) is capturing investor attention with a remarkable potential upside of 56.22%, according to analyst ratings. This biopharmaceutical company, based in Ramsey, New Jersey, is making..

Integer Holdings Corporation (ITGR) Stock Analysis: Navigating the Medical Device Landscape with Strategic Growth

Integer Holdings Corporation (NYSE: ITGR) stands as a formidable player in the healthcare sector, specifically within the medical devices industry. With a market capitalization of $3.03 billion, Integer operates on..

Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis: Assessing a Potential 9.97% Upside in the Biotechnology Sector

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), a stalwart in the biotechnology industry, has positioned itself as a critical player in the healthcare sector with its diverse portfolio of groundbreaking treatments and..

Telix Pharmaceuticals Limited (TLX): Investor Outlook Highlights 206% Upside Potential

Telix Pharmaceuticals Limited (TLX), an emerging titan in the healthcare sector, is captivating investor attention with its promising pipeline and a striking potential upside of 206.21%. As a commercial-stage biopharmaceutical..

Henry Schein, Inc. (HSIC) Stock Analysis: Evaluating Its Unique Position in the Medical Distribution Sector

Henry Schein, Inc. (NASDAQ: HSIC) stands as a formidable player in the healthcare sector, specifically within the medical distribution industry. With a robust market capitalization of $9.67 billion, the company..

Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Unpacking a 15% Potential Upside

Bio-Rad Laboratories, Inc. (NYSE: BIO), a key player in the healthcare sector, is drawing significant attention from investors with its promising 15.42% potential upside. Specializing in medical devices, Bio-Rad is..

TransMedics Group, Inc. (TMDX) Stock Analysis: A Healthcare Innovator with 6.77% Potential Upside

TransMedics Group, Inc. (TMDX) has been capturing the attention of investors with its pioneering approach in the medical devices sector, particularly in the field of organ transplant therapy. Operating out..

Nuvalent, Inc. (NUVL): Analyst Ratings Signal 36.79% Upside in Biotech Innovator

Nuvalent, Inc. (NASDAQ: NUVL), a clinical-stage biopharmaceutical company, stands out in the biotechnology sector with a market capitalization of $8.04 billion. Headquartered in Cambridge, Massachusetts, Nuvalent is making significant strides..

Lantheus Holdings, Inc. (LNTH) Stock Analysis: Unlocking a 28.62% Potential Upside for Investors

Lantheus Holdings, Inc. (NASDAQ: LNTH) stands as a formidable player in the healthcare sector, with a particular focus on the specialty and generic drug manufacturing industry. This Bedford, Massachusetts-based company..

Waystar Holding Corp. (WAY) Stock Analysis: A 90.80% Potential Upside Amid Robust Analyst Support

Waystar Holding Corp. (NASDAQ: WAY), a key player in the healthcare information services sector, is capturing the attention of investors with its promising growth potential and strong analyst support. Founded..

AptarGroup, Inc. (ATR) Stock Analysis: A 19% Upside Potential in the Healthcare Sector

AptarGroup, Inc. (NYSE: ATR), a leading player in the healthcare sector specializing in medical instruments and supplies, stands out as a compelling investment opportunity with a noteworthy 19.02% potential upside..

Smith & Nephew SNATS, Inc. (SNN) Stock Analysis: Evaluating a Potential 4.99% Upside in the Healthcare Sector

Smith & Nephew SNATS, Inc. (NYSE: SNN), a stalwart in the healthcare sector, particularly in the medical devices industry, is attracting attention from investors with an intriguing potential upside of..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds